AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35844134
Drug: Brivaracetam (BRV)
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Brivaracetam (BRV) monotherapy
Trial: 35015856
Drug: standard micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard micronutrient powder (MNP) containing 4.1 mg zinc and 10 mg iron, daily
Trial: 35015856
Drug: high-zinc (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-zinc (10 mg), low-iron (6 mg) (HiZn LoFe) MNP, daily
Trial: 35015856
Drug: HiZn (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HiZn (10 mg) LoFe (6 mg)/HiZn (10 mg), no-iron MNPs on alternating days
Trial: 35015856
Drug: dispersible zinc
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dispersible zinc tablet (10 mg), daily
Trial: 35015856
Drug: dispersible zinc
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dispersible zinc tablet (10 mg), daily for 2 wk at enrollment and 12 wk
Trial: 35015856
Drug: placebo powder,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo powder, daily
Trial: 33310174
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g leucine
Trial: 33310174
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g isoleucine
Trial: 33876547
Drug: Smartphone-controlled patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-controlled patch electro-acupuncture (SCEA)
Trial: 35123694
Drug: Standard-of-care (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (intravenous paclitaxel, pegylated liposomal doxorubicin, topotecan, oral letrozole, or oral tamoxifen)
Trial: 34559801
Drug: Azithromycin (20mg/kg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (20mg/kg, biannual single-dose)
Trial: 34491646
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (oxiracetam capsules, 2 capsules, 3 times a day)
Trial: 36330567
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug use (sertraline, fluvoxamine, risperidone, fluoxetine)
Trial: 33634319
Drug: Low-iron MNP
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-iron MNP (5 mg iron)
Trial: 35179586
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg) with capecitabine (850 or 1000 mg/m2) and bevacizumab (7.5 mg/kg)
Trial: 35179586
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with capecitabine (850 or 1000 mg/m2) and bevacizumab (7.5 mg/kg)
Trial: 35179586
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg) with capecitabine and bevacizumab
Trial: 34949156
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual with systematic client feedback (SCF) based on the Partners for Change Outcome Management System (PCOMS)
Trial: 35724857
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (3 mg/kg/day)
Trial: 35724857
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (10 mg/kg/day)
Trial: 32650818
Drug: Hydroxychloroquine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (600 mg first dose, then 200 mg twice daily for 7 days, total 3 g)
Trial: 32650818
Drug: Placebo (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equivalent number of capsules to Hydroxychloroquine)
Trial: 35881180
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment with sorafenib (either alone or combined with locoregional therapies)
Trial: 33789555
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (Limosilactobacillus fermentum LF16, Lacticaseibacillus rhamnosus LR06, Lactiplantibacillus plantarum LP01, Bifidobacterium longum 04)
Trial: 33789555
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (maltodextrin)
Trial: 32506922
Drug: mHealth intervention
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth intervention (electronic medication tray and mHealth app)
Trial: 36163020
Drug: Camostat mesilate
RxNorm normalized name: Camostat mesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camostat mesilate (600 mg qid for up to 14 days)
Trial: 33611132
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) or Relaxation Training (RT)
Trial: 33479721
Drug: 80-mg ixekizumab
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80-mg ixekizumab (IXE) every 2 weeks
Trial: 33479721
Drug: 80-mg ixekizumab
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80-mg ixekizumab (IXE) every 4 weeks
Trial: 33479721
Drug: 80-mg ixekizumab
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80-mg ixekizumab (IXE)
Trial: 33602996
Drug: BIAsp 30
RxNorm normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BIAsp 30 plus metformin
Trial: 34240455
Drug: TAK-071 40-80
RxNorm normalized name: TAK-071
DrugBank: TAK-071 (DB18954)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-071 40-80 mg
Trial: 34240455
Drug: TAK-071 120-160
RxNorm normalized name: TAK-071
DrugBank: TAK-071 (DB18954)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-071 120-160 mg
Trial: 34240455
Drug: TAK-071 (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-071 (high doses)
Trial: 33017484
Drug: Daily plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily plasma exchange and oral prednisone
Trial: 32990214
Drug: HUG116 tablet;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HUG116 tablet; tenofovir disoproxil
Trial: 32990214
Drug: Viread tablet;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viread tablet; tenofovir disoproxil fumarate
Trial: 36057498
Drug: Warmed intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed intravenous fluid (37°C)
Trial: 39415923
Drug: Pirtobrutinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirtobrutinib monotherapy
Trial: 36164121
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice of covalent BTK inhibitor monotherapy (ibrutinib, acalabrutinib, or zanubrutinib)
Trial: 37755683
Drug: Multicomponent exercise
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent exercise program including supervised walking, squat, balance, and inspiratory muscle training (IMT) with two daily sessions.
Trial: 32053067
Drug: Various pharmaceutical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Various pharmaceutical agents (gonadotropins, anti‐estrogen agents, aromatase inhibitors)
Trial: 34265312
Drug: Propranolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (1 mg/kg po QID)
Trial: 39053954
Drug: Placebo (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equivalent dose)
Trial: 32593228
Drug: E-learning on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-learning on smartphones with interactive learning materials including videos of dental treatments
Trial: 33908131
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration in humans
Trial: 33908131
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration in Ghsr knockout and wild-type rats
Trial: 33908131
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration versus calorically equivalent non-alcoholic sucrose solution in rats
Trial: 33908131
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration on ghrelin secretion from gastric mucosa cells ex vivo
Trial: 35932720
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (10 UI once a day for 7 days)
Trial: 35932720
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (control group, once a day for 7 days)
Trial: 32643076
Drug: No antibiotics/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics/placebo
Trial: 35211743
Drug: Roluperidone 64
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roluperidone 64 mg/day
Trial: 35211743
Drug: Roluperidone 32
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roluperidone 32 mg/day
Trial: 35662406
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg bodyweight orally three times per week)
Trial: 34697034
Drug: A. soehngenii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A. soehngenii infusion
Trial: 37656449
Drug: Prophylactic ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prophylactic ranibizumab (PR) injections every 3 months
Trial: 32306247
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec 200 units/mL
Trial: 32306247
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300 units/mL
Trial: 36074760
Drug: Tighter glycaemic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tighter glycaemic targets (FPG ≤5.0 mmol/L, 1-hour ≤7.4 mmol/L, 2-hour postprandial ≤6.7 mmol/L)
Trial: 36074760
Drug: Less tight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less tight glycaemic targets (FPG <5.5 mmol/L, 1-hour <8.0 mmol/L, 2-hour postprandial <7.0 mmol/L)
Trial: 32699911
Drug: Flaxseed muffins
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed muffins (30 g total, consumed once in the morning)
Trial: 32699911
Drug: Flaxseed muffins
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed muffins (10 g per muffin, consumed three times a day)
Trial: 32699911
Drug: Control muffins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control muffins (0 g flaxseed, consumed three times a day)
Trial: 33308907
Drug: Daily disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily disposable toric contact lenses
Trial: 33961006
Drug: Colchicine (0.5-1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.5-1.0 mg daily)
Trial: 32594766
Drug: LDL-C target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C target of <70 mg/dL
Trial: 32594766
Drug: LDL-C target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C target of 100±10 mg/dL
Trial: 33774942
Drug: Topical ozonated
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ozonated sunflower oil (950 peroxide value) applied daily for one week
Trial: 33774942
Drug: Non-ozonated sunflower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ozonated sunflower oil (control) applied daily for one week
Trial: 33774942
Drug: Topical ozonated
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ozonated sunflower oil
Trial: 34772441
Drug: Oral antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotic treatment after 2 weeks of IV antibiotic therapy
Trial: 34772441
Drug: Standard 6-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 6-8 weeks of IV antibiotics
Trial: 34772441
Drug: Standard IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard IV antibiotics
Trial: 35079029
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (INI) and Placebo
Trial: 34509600
Drug: l-glutamine
RxNorm normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-glutamine
Trial: 35600633
Drug: AYUSH 64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AYUSH 64 (3 gm per day in three divided doses for 14 days)
Trial: 33471548
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment arm (77 Gy, fractions of 2.2 Gy)
Trial: 34407771
Drug: Digital intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital intervention and Treatment as usual
Trial: 32192275
Drug: Ramosetron (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron (0.3 mg intravenously) combined with Aprepitant (125 mg orally, D1 and 80 mg orally, D2-3) and Dexamethasone (12 mg orally or intravenously, D1 and 8 mg orally, D2-4)
Trial: 32192275
Drug: Palonosetron (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron (0.25 mg intravenously) combined with Aprepitant (125 mg orally, D1 and 80 mg orally, D2-3) and Dexamethasone (12 mg orally or intravenously, D1 and 8 mg orally, D2-4)
Trial: 33419188
Drug: CRT (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT (50 Gy with oral capecitabine)
Trial: 35612708
Drug: Finerenone 20
RxNorm normalized name: finerenone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone 20 mg with high-fat, high-calorie meal
Trial: 35612708
Drug: Finerenone 10
RxNorm normalized name: finerenone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone 10 mg with omeprazole
Trial: 35612708
Drug: Finerenone 10
RxNorm normalized name: finerenone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone 10 mg with Maalox
Trial: 34002953
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with pioglitazone plus exenatide or insulin
Trial: 33091455
Drug: Nonsurgical endodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical endodontic treatment (NSET)
Trial: 33091455
Drug: Nonsurgical endodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical endodontic treatment (NSET) combined with vital pulp therapy (VPT)
Trial: 32563188
Drug: Dual trigger
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual trigger (GnRH agonist and hCG)
Trial: 37723993
Drug: Oral sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sildenafil citrate, administered after onset of labor
Trial: 33248439
Drug: Menthol energy
RxNorm normalized name: Menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menthol energy gel (0.5% concentration)
Trial: 33248439
Drug: Menthol energy
RxNorm normalized name: Menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menthol energy gel (0.1% concentration)
Trial: 33172865
Drug: Teprotumumab treatment
RxNorm normalized name: Teprotumumab
DrugBank: Teprotumumab (DB06343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teprotumumab treatment for 24 weeks
Trial: 34929814
Drug: Moringa oleifera
RxNorm normalized name: Moringa Oleifera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moringa oleifera leaf capsules
Trial: 34929814
Drug: TTD capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTD capsules
Trial: 32907566
Drug: Navafenterol 400
RxNorm normalized name: Navafenterol
DrugBank: Navafenterol (DB19195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navafenterol 400 μg
Trial: 32907566
Drug: Navafenterol 1800
RxNorm normalized name: Navafenterol
DrugBank: Navafenterol (DB19195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navafenterol 1800 μg
Trial: 36343472
Drug: Automated virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated virtual reality therapy (gameChange)
Trial: 33231847
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy group intervention (8 sessions)
Trial: 36093920
Drug: Adalimumab adjunct
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab adjunct to sertraline
Trial: 36093920
Drug: Placebo adjunct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo adjunct to sertraline
Trial: 32360313
Drug: NACP on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NACP on the base formulation (with 20 wt.% NACP)
Trial: 32360313
Drug: NACP on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NACP on the antibacterial formulation (with 20 wt.% NACP and 5 wt.% DMAHDM)
Trial: 32360313
Drug: Base formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Base formulation (without NACP and DMAHDM)
Trial: 35438671
Drug: NLTX (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLTX (50 mg)
Trial: 34218768
Drug: Pharmacist-led systematic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led systematic medication review
Trial: 32017816
Drug: EEG Biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EEG Biofeedback therapy
Trial: 38986575
Drug: Tailored treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored treatment plans
Trial: 34923994
Drug: Aprepitant (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (80 mg daily)
Trial: 34923994
Drug: Hydroxyzine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine (25 mg daily)
Trial: 36055414
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg caffeinated drink (CAF)
Trial: 34477122
Drug: Standard lymphadenectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard lymphadenectomy with postoperative adjuvant chemotherapy (SG)
Trial: 34477122
Drug: Extended lymphadenectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended lymphadenectomy with postoperative adjuvant chemotherapy (EG)
Trial: 33463088
Drug: Generic obeticholic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic obeticholic acid (10 mg)
Trial: 32573860
Drug: Tetrahydrocurcumin (THC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrahydrocurcumin (THC) 40 mg/kg for 3 days
Trial: 32141126
Drug: Soluble dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble dietary fiber (SDF) 20-g/d polydextrose
Trial: 32141126
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (same EN solution without SDF)
Trial: 35222874
Drug: Ultrasound-guided 18G-PTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided 18G-PTC puncture needle therapy
Trial: 35222874
Drug: Small needle-knife
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small needle-knife therapy
Trial: 34488841
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of colchicine
Trial: 36942113
Drug: Buccal Mucosa
RxNorm normalized name: Diazepam 5 MG Buccal mucosa Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal Mucosa Graft Urethroplasty (Group B)
Trial: 32090492
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field therapy (PEMF) delivered on perineal area 5 minutes twice daily for 28 days
Trial: 33176660
Drug: Traditional medications
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional medications (RAAS blockers)
Trial: 33176660
Drug: Dapagliflozin added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin added to traditional medications
Trial: 35118763
Drug: PACT (Physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PACT (Physiotherapy informed by Acceptance and Commitment Therapy)
Trial: 32433572
Drug: Chlorhexidine-chitosan gel
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine-chitosan gel
Trial: 32433572
Drug: Neutral water-based
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral water-based gel (placebo)
Trial: 34348352
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate 0.1% cream (BMV)